Edition:
United Kingdom

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

11.15USD
20 Jul 2018
Change (% chg)

$-0.07 (-0.62%)
Prev Close
$11.22
Open
$11.26
Day's High
$11.34
Day's Low
$11.09
Volume
607,082
Avg. Vol
1,760,955
52-wk High
$12.52
52-wk Low
$5.28

Latest Key Developments (Source: Significant Developments)

Endo, Bayer defeat Custopharm appeal over Aveed patents
Friday, 13 Jul 2018 

July 13 (Reuters) - Endo, bayer defeat appeal by custopharm over validity of patents related to testosterone replacement therapy aveed -- u.s. Court ruling:.  Full Article

Lannett Acquires Portfolio Of Generic Products From Endo International
Monday, 7 May 2018 

May 7 (Reuters) - Lannett Company Inc ::LANNETT ACQUIRES PORTFOLIO OF GENERIC PRODUCTS FROM ENDO INTERNATIONAL.LANNETT COMPANY INC - TRANSACTION INCLUDES 23 APPROVED AND 1 PENDING DRUG PRODUCT APPLICATIONS, PRIMARILY ORAL SOLUTIONS.LANNETT - ACQUIRED 23 APPROVED AND ONE PENDING DRUG PRODUCT APPLICATIONS FROM UNIT OF ENDO FOR UPFRONT PAYMENT PLUS FUTURE MILESTONE PAYMENTS.LANNETT - EXPECT TO BEGIN LAUNCHING PRODUCTS, AFTER TRANSFER ACTIVITIES ARE COMPLETED, REGULATORY FILINGS MADE, ESTIMATED TO BE IN H2 2019.  Full Article

Endo International Receives Paragraph IV Notification On Vasostrict
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Endo International PLC ::ENDO RECEIVES PARAGRAPH IV NOTIFICATION ON VASOSTRICT.ENDO INTERNATIONAL-LETTER CONTAINS CERTIFICATIONS ALLEGING INVALIDITY,NON-INFRINGEMENT FOR 5 PATENTS CO LISTED IN APPROVED DRUG PRODUCTS FOR VASOSTRICT.ENDO IS ASSESSING DETAILS OF NOTICE LETTER AND FORMULATING ITS LEGAL STRATEGY.ENDO INTERNATIONAL - NOTICE LETTER ADVISING THAT EAGLE PHARMACEUTICALS SUBMITTED ANDA TO FDA SEEKING APPROVAL TO MARKET GENERIC VERSION OF VASOSTRICT.  Full Article

Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
Monday, 16 Apr 2018 

April 16 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA.EAGLE PHARMACEUTICALS INC - PRODUCT IS GENERIC VERSION OF ENDO INTERNATIONAL PLC'S ORIGINAL VASOSTRICT FORMULATION.  Full Article

Endo International says No Proceedings Have Currently Been Initiated Against EPI As Result Of Subpoena
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Endo International Plc ::ENDO INTERNATIONAL - TO ENDO'S KNOWLEDGE, NO PROCEEDINGS HAVE CURRENTLY BEEN INITIATED AGAINST EPI AS A RESULT OF SUBPOENA - SEC FILING.  Full Article

Endo Comments On U.S. Attorney's Office Grand Jury Subpoena Relating To Products Containing Oxymorphone
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Endo International Plc ::ENDO COMMENTS ON UNITED STATES ATTORNEY'S OFFICE GRAND JURY SUBPOENA RELATING TO PRODUCTS CONTAINING OXYMORPHONE.ENDO INTERNATIONAL - UNIT ENDO PHARMACEUTICALS RECEIVED GRAND JURY SUBPOENA FROM UNITED STATES ATTORNEY'S OFFICE FOR SOUTHERN DISTRICT OF FLORIDA.ENDO - ‍SUBPOENA REQUESTS DISTRIBUTION,THIRD PARTY AGREEMENTS,DOCUMENTS ON INTERACTIONS WITH GOVERNMENT. AGENCIES RELATED TO PRODUCTS CONTAINING OXYMORPHONE​.  Full Article

Glenview Capital Management reports 6.70 pct passive stake in Endo
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Glenview Capital Management Llc::Glenview Capital Management Llc reports 6.70 percent passive stake in Endo International Plc as on October 31, 2017 - SEC filing‍​.  Full Article

Endo posts Q3 adjusted earnings per share $0.91
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Endo International Plc :Endo reports third-quarter 2017 financial results.Q3 adjusted earnings per share $0.91 from continuing operations.Q3 GAAP loss per share $0.45 from continuing operations.Q3 revenue $787 million versus I/B/E/S view $784.9 million.Q3 earnings per share view $0.71 -- Thomson Reuters I/B/E/S.Endo International - ‍for full twelve months ended december 31, 2017, at current exchange rates, Endo is reaffirming its full-year guidance on revenue​.Endo - ‍for full 12 months ended Dec 31, 2017, at current exchange rates, is reaffirming FY guidance on adjusted diluted EPS from continuing operations​.Endo International Plc - ‍during third-quarter 2017, company recorded pre-tax, non-cash asset impairment charges of $95 million​.Endo International Plc - sees FY ‍reported diluted GAAP loss per share from continuing operations to be between $4.94 and $4.64​.FY2017 earnings per share view $3.55, revenue view $3.47 billion -- Thomson Reuters I/B/E/S.  Full Article

Endo sees Q3 ‍revenues of about $785 million​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Endo International Plc :Endo announces certain preliminary financial results for third-quarter 2017 and affirms selected 2017 financial guidance.Sees FY 2017 revenue $3.38 billion to $3.53 billion.Q3 adjusted earnings per share $0.85 from continuing operations.Q3 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Endo International Plc - Sees Q3 ‍revenues of approximately $785 million​.Q3 revenue view $784.9 million -- Thomson Reuters I/B/E/S.FY2016 revenue view $3.92 billion -- Thomson Reuters I/B/E/S.Endo International Plc - ‍Expects 2017 adjusted EPS from continuing operations to be at upper end of guidance ranges of $3.35 to $3.65​.FY2017 earnings per share view $3.52, revenue view $3.47 billion -- Thomson Reuters I/B/E/S.Endo International Plc - Qtrly ‍preliminary​ reported (GAAP) loss per share from continuing operations of about $0.45.Endo - ‍"Unaware" of any unapproved, non-sterile-to-sterile compounding facilities currently selling/distributing Vasopressin injection product​.  Full Article

Endo files federal lawsuit to obtain FDA compliance
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Endo International Plc :Endo files federal lawsuit to obtain FDA compliance with drug quality and security act of 2013.Endo International - ‍lawsuit seeks immediate removal of vasopressin from FDA's Category 1 nominations list.Endo - Units filed suit in court against FDA seeking declaration that FDA's current framework allowing bulk compounding of numerous products is unlawful.Endo - seek removal of vasopressin from FDA's Category 1 nominations list to avoid bulk compounding of vasopressin ‍​by non-sterile-to-sterile outsourcing facilities‍​.  Full Article

UPDATE 1-UK's Indivior will fight U.S. FDA's approval for copycat drug

* Shares down 23 pct at 1427 GMT (Adds company comments, outlook, background, strategy)